Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price has languished in 2024 while the market has flourished.

During the period, the biotechnology giant's shares have lost approximately 3% of their value.

This compares unfavourably to the performance of the ASX 200 index, which is up over 10% year to date. And that excludes the dividends paid over the period, which add somewhere in the region of 4%.

Perhaps the most disappointing part of this is that over the past couple of decades, the CSL share price has built a reputation of being a market-beater.

But we just simply have not seen this since the pandemic for a number of reasons. Since late 2019, CSL's shares have gone sideways.

But those lost years could be a thing of the past in the near future with analysts tipping CSL to find its way again.

A group of men in the office celebrate after winning big.

Image source: Getty Images

CSL share price tipped to rise strongly

According to a recent note out of Bell Potter, its analysts believe that the company is about to embark on a journey of strong and consistent growth.

In light of this, its analysts feel that the CSL share price is now being undervalued by the market.

Commenting on why it thinks now could be a good time to invest in the company, the broker said:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for double-digit earnings growth driven by the core Behring division.

The note reveals that Bell Potter has a buy rating and $345.00 price target on CSL's shares. Based on its current share price of $280.74, this implies potential upside of almost 17% for investors over the next 12 months.

To put this into context, a $5,000 investment in the company would turn into approximately $5,800 by this time next year if Bell Potter is on the money with its recommendation.

Overall, this could make CSL a great option for investors that are wanting to add some high-quality stocks to their portfolio for 2025.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Could CSL shares really hit $200? Experts reveal their 12-month targets

Brokers warn CSL’s spectacular rebound doesn’t guarantee further gains.

Read more »

Five healthcare workers standing together and smiling.
ASX Share Market News

ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus

Healthcare outperformed while the ASX 200 weakened as earnings season continued last week.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Telix shares are tumbling. Is the stock finally at fair value?

Telix's sell-off reflects valuation, competition, and heightened growth expectations.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why I'd buy Medibank shares for the dividend yield

Medibank is providing investors with very healthy dividends.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Fisher & Paykel Healthcare shares: Earnings outlook upgraded for FY27

Here's what the company expects to report for FY 2027.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Test Only

Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook

Pacific Edge’s FY26 loss grew, but US Medicare draft coverage for its diagnostic tests supports a more positive outlook going…

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Why I'd buy CSL, Cochlear, and Pro Medicus shares

These are three ASX healthcare shares I would be happy to own for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Earnings Results

Sonic Healthcare share price in focus on FY26 profit jump and digital push

The healthcare company is paying total dividends of $1.08 per share in FY 2026.

Read more »